Your session is about to expire
← Back to Search
Dose Escalation Extension Group for Cutaneous Lichen Planus
Study Summary
This trial is testing a new drug to see if it's safe and effective in treating a skin condition called Cutaneous Lichen Planus.
- Cutaneous Lichen Planus
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any similar investigations to the one being conducted with Baricitinib (LY3009104)?
"At this moment, 34 separate studies are being conducted to study the efficacy of Baricitinib (LY3009104). Of these, 17 trials are in Phase 3. The many trials for Baricitinib (LY3009104) originate from Pune, Maharashtra but can be found at 1439 different locations."
Are we still able to add people to this experiment?
"Yes, the trial is still open and recruiting patients. According to the information on clinicaltrials.gov, the posting date was 1/11/2022 and there have been no updates since then. They are looking for a total of 12 participants at 1 site."
For what medical conditions is Baricitinib (LY3009104) most often prescribed?
"Baricitinib (LY3009104) is an effective treatment for hospitalized patients with coronavirus disease 2019 (covid‑19) who are using extracorporeal membrane oxygenation."
How many people can join this clinical trial at the very most?
"That is correct, the trial information on clinicaltrials.gov does show that recruitment is still open for this study. The posting date was 1/11/2022 and there have been no edits since then. They are looking to enroll 12 patients total from 1 location."
Does Baricitinib (LY3009104) have a lot of reported side effects?
"While there is some evidence to support the safety of Baricitinib (LY3009104), it only received a 2 because, as a Phase 2 drug, no efficacy data has been collected yet."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- Mayo Clinic in Arizona: < 24 hours
Typically responds via
Share this study with friends
Copy Link
Messenger